Home > Pressemitteilung: On the way to curing type 1 diabetes ... MHH team aims to intervene in the autoimmune process and stop the destruction of insulin-producing beta cells in the pancreas ...

Lilly has also submitted marketing applications for Mirikizumab-mrkz in Crohn’s disease around the globe, including in the ...

For people with diabetes, the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with a reduced risk for certain disorders and conditions, including neurocognitive and ...

Glucagon-like peptide 1 receptor agonists (GLP1RA)—medications for type 2 diabetes and obesity that have recently been making headlines due to a rise in popularity as weight loss agents—have been ...

Canary Cure Therapeutics (Canary Global Inc.) has released preclinical results for its lead candidate, CCT-217, an siRNA therapeutic targeting cannabinoid CB1 receptor (CB1R) and zinc finger protein ...

Glucagon-like peptide-1 receptor agonist use corresponded with risk reductions for dozens of diseases and adverse health ...

A new study compares the benefits and risks of taking GLP-1 medications for weight loss, including risks of dementia, ...

A new research paper was published in Oncotarget's Volume 16 on January 20, 2025, titled "Anti-correlation of KLRG1 and PD-1 expression in human tumor CD8 T cells." ...

Shares of oilfield services provider Flowco jumped in their market debut on Thursday, as they opened for trading 21% above ...

Below is a review of novel drug and biological products approved by the Food and Drug Administration (FDA) in 2024. The list includes several groundbreaking therapies that are expected to change the ...

Asthma represents a substantial health burden in childhood globally, with minoritised populations being disproportionately impacted.1 Recent literature has increasingly linked social determinants of ...

Despite the recent rise in herbal supplement use, research suggests certain supplements may pose risks for patients with ...